Clinical Trials
12 trialsNCT05889390 2026-05-15
NeoHTerMa
Semmelweis University
Phase 2/3 Active not recruiting
NCT06926868 2026-04-30
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07544056 2026-04-22
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2/3 Not yet recruiting
NCT06910072 2025-04-04
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Not yet recruiting
NCT05426486 2024-10-30
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2/3 Active not recruiting
NCT03150576 2022-11-14
PARTNER
Cambridge University Hospitals NHS Foundation Trust
Phase 2/3 Recruiting
NCT01057069 2022-10-12
neo-TN
The Netherlands Cancer Institute
Phase 2/3 Active not recruiting
NCT03674242 2022-08-01
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)
ERYtech Pharma
Phase 2/3 Terminated
NCT04907344 2021-05-28
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT00448266 2021-01-22
Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT01881230 2019-02-21
tnAcity
Celgene
Phase 2/3 Completed
NCT01426880 2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3 Completed